Pulmonary Arterial Hypertension Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Merck Inc., United Therapeutics, United Therapeutics, Aerovate

Posted on
by

Pulmonary Arterial Hypertension Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Merck Inc., United Therapeutics, United Therapeutics, Aerovate
DelveInsight’s “Pulmonary Arterial Hypertension Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Pulmonary Arterial Hypertension.

DelveInsight’s “Pulmonary Arterial Hypertension Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Pulmonary Arterial Hypertension, historical and forecasted epidemiology as well as the Pulmonary Arterial Hypertension market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Pulmonary Arterial Hypertension market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pulmonary Arterial Hypertension Market Forecast

 

Some of the key facts of the Pulmonary Arterial Hypertension Market Report: 

  • The Pulmonary Arterial Hypertension market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • With just 31,931 cases with verified diagnoses in 2019, the estimated total prevalence in the US was 53,219 cases. Around 80% of all diagnosed cases in the US were in the female patient population. Data from the “Medicare Claim database” was used to calculate the prevalence of pulmonary arterial hypertension in the US
  • Segovia-Cubero et al. (2020) estimated that 30-35 PAH units are functioning in Spain (based on information from the REHAP registry). Despite improvements in PAH treatment,6–10 there is still a sizable percentage of patients with incorrect diagnoses and unsuitable PAH treatment in clinical practice
  • The prevalence of Pulmonary Arterial Hypertension (PAH) reached 69,605 cases in the 7MM in 2021, and it is predicted that number will rise by 2032
  • France reported 3,396 instances of PAH, which was the most among the EU4 nations in terms of prevalence in 2021
  • Key Pulmonary Arterial Hypertension Companies: Merck & Company Inc., United Therapeutics, United Therapeutics, Aerovate Therapeutics, Respira Therapeutics, Actelion, Insmed Incorporated, Novartis, Cereno Scientific AB, Merck Sharp & Dohme, Vigonvita Life Sciences, Janssen Pharmaceutical, and others
  • Key Pulmonary Arterial Hypertension Therapies: Sotatercept, Ralinepag, Rodatristat Ethyl, AV-101, RT234, Parenteral Treprostinil, Epoprostenol, Treprostinil Palmitil, Imatinib mesylate, CS1, MK-5475, TPN171H, Macitentan, and others
  • The Pulmonary Arterial Hypertension epidemiology based on gender analyzed that the prevalence of Pulmonary Arterial Hypertension (PAH) is more among female as compared to male
  • The Pulmonary Arterial Hypertension market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pulmonary Arterial Hypertension pipeline products will significantly revolutionize the Pulmonary Arterial Hypertension market dynamics.

 

Pulmonary Arterial Hypertension Overview

The tiny pulmonary arterioles are largely affected by the progressive condition known as pulmonary arterial hypertension (PAH). A subset of patients who also have precapillary hypertension and have pulmonary artery wedge pressure less than 15 mm Hg and pulmonary vascular resistance larger than 3 Woods units are referred to as having PAH.

 

Get a Free sample for the Pulmonary Arterial Hypertension Market Report 

https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-market

 

Pulmonary Arterial Hypertension Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Pulmonary Arterial Hypertension Epidemiology Segmentation:

The Pulmonary Arterial Hypertension market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Pulmonary Arterial Hypertension
  • Prevalent Cases of Pulmonary Arterial Hypertension by severity
  • Gender-specific Prevalence of Pulmonary Arterial Hypertension
  • Diagnosed Cases of Episodic and Chronic Pulmonary Arterial Hypertension

 

Download the report to understand which factors are driving Pulmonary Arterial Hypertension epidemiology trends @ Pulmonary Arterial Hypertension Epidemiology Forecast

 

Pulmonary Arterial Hypertension Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pulmonary Arterial Hypertension market or expected to get launched during the study period. The analysis covers Pulmonary Arterial Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Pulmonary Arterial Hypertension Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Pulmonary Arterial Hypertension Therapies and Key Companies

  • Sotatercept: Merck & Company Inc.
  • Ralinepag: United Therapeutics
  • Rodatristat Ethyl: Altavant Sciences
  • AV-101: Aerovate Therapeutics
  • RT234: Respira Therapeutics
  • Parenteral Treprostinil: United Therapeutics
  • Epoprostenol: Actelion
  • Treprostinil Palmitil: Insmed Incorporated
  • Imatinib mesylate: Novartis
  • CS1: Cereno Scientific AB
  • MK-5475: Merck Sharp & Dohme
  • TPN171H: Vigonvita Life Sciences
  • Macitentan: Janssen Pharmaceutical

 

Discover more about therapies set to grab major Pulmonary Arterial Hypertension market share @ Pulmonary Arterial Hypertension Treatment Market

 

Scope of the Pulmonary Arterial Hypertension Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Pulmonary Arterial Hypertension Companies: Merck & Company Inc., United Therapeutics, United Therapeutics, Aerovate Therapeutics, Respira Therapeutics, Actelion, Insmed Incorporated, Novartis, Cereno Scientific AB, Merck Sharp & Dohme, Vigonvita Life Sciences, Janssen Pharmaceutical, and others
  • Key Pulmonary Arterial Hypertension Therapies: Sotatercept, Ralinepag, Rodatristat Ethyl, AV-101, RT234, Parenteral Treprostinil, Epoprostenol, Treprostinil Palmitil, Imatinib mesylate, CS1, MK-5475, TPN171H, Macitentan, and others
  • Pulmonary Arterial Hypertension Therapeutic Assessment: Pulmonary Arterial Hypertension current marketed and Pulmonary Arterial Hypertension emerging therapies
  • Pulmonary Arterial Hypertension Market Dynamics: Pulmonary Arterial Hypertension market drivers and Pulmonary Arterial Hypertension market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Pulmonary Arterial Hypertension Unmet Needs, KOL’s views, Analyst’s views, Pulmonary Arterial Hypertension Market Access and Reimbursement 

 

To know more about Pulmonary Arterial Hypertension companies working in the treatment market, visit @ Pulmonary Arterial Hypertension Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Pulmonary Arterial Hypertension Market Report Introduction

2. Executive Summary for Pulmonary Arterial Hypertension

3. SWOT analysis of Pulmonary Arterial Hypertension

4. Pulmonary Arterial Hypertension Patient Share (%) Overview at a Glance

5. Pulmonary Arterial Hypertension Market Overview at a Glance

6. Pulmonary Arterial Hypertension Disease Background and Overview

7. Pulmonary Arterial Hypertension Epidemiology and Patient Population

8. Country-Specific Patient Population of Pulmonary Arterial Hypertension 

9. Pulmonary Arterial Hypertension Current Treatment and Medical Practices

10. Pulmonary Arterial Hypertension Unmet Needs

11. Pulmonary Arterial Hypertension Emerging Therapies

12. Pulmonary Arterial Hypertension Market Outlook

13. Country-Wise Pulmonary Arterial Hypertension Market Analysis (2019–2032)

14. Pulmonary Arterial Hypertension Market Access and Reimbursement of Therapies

15. Pulmonary Arterial Hypertension Market Drivers

16. Pulmonary Arterial Hypertension Market Barriers

17.  Pulmonary Arterial Hypertension Appendix

18. Pulmonary Arterial Hypertension Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services